Pfizer Secures Global Rights To China’s 3SBio’s Cancer Drug In $6 Billion Deal

All NewsMay 20, 2025

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.’s bispecific antibody SSGJ-707.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent